2023
Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City
Pandey A, Fitzpatrick M, Moghadas S, Vilches T, Ko C, Vasan A, Galvani A. Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City. The Lancet Regional Health - Americas 2023, 24: 100555. PMID: 37554154, PMCID: PMC10405058, DOI: 10.1016/j.lana.2023.100555.Peer-Reviewed Original ResearchHealthcare costsVaccine dosesInfluenza vaccine coverageCOVID-19 illnessDirect healthcare costsSevere health outcomesCOVID-19 vaccineCOVID-19 burdenNew York CityBooster vaccineVaccine coverageVaccination ratesBivalent vaccineBase case scenarioHealth outcomesEligible residentsProbable casesDisease controlVaccineCanadian InstituteCOVID-19VaccinationHealth researchCommonwealth FundOutcomes
2022
Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
Du Z, Wang L, Pandey A, Lim WW, Chinazzi M, Piontti APY, Lau EHY, Wu P, Malani A, Cobey S, Cowling BJ. Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nature Medicine 2022, 28: 934-938. PMID: 35210596, PMCID: PMC9117137, DOI: 10.1038/s41591-022-01736-z.Peer-Reviewed Original ResearchConceptsLarge-scale survey dataEconomic benefitsFull dose vaccinationSurvey dataHospital admission costsDose-sparing strategiesCost of hospitalizationCOVID-19 deathsPopulation-level transmissionVaccine dosesVaccination strategiesAdmission costsEconomic burdenVaccine shortageFractional dosesVaccinationDose fractionationHigh transmissibilityVaccine distributionCostPublic healthVaccineWillingnessDosesIndia
2020
Prosocial polio vaccination in Israel
Wells CR, Huppert A, Fitzpatrick MC, Pandey A, Velan B, Singer BH, Bauch CT, Galvani AP. Prosocial polio vaccination in Israel. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 13138-13144. PMID: 32457142, PMCID: PMC7293608, DOI: 10.1073/pnas.1922746117.Peer-Reviewed Original ResearchConceptsOral polio vaccineOPV campaignsPolio vaccineVaccination behaviorInactivated polio vaccineGreater vaccination coverageRisk of paralysisProsocial vaccinationVaccination coverageVaccine campaignPolio vaccinationVaccinationInsufficient vaccinationPoliomyelitis eradicationSurveillance programVaccineSporadic outbreaksIsrael MinistryPrimary objectiveProsocial natureParalysisDiseasePolio
2019
Ebola vaccination in the Democratic Republic of the Congo
Wells CR, Pandey A, Parpia AS, Fitzpatrick MC, Meyers LA, Singer BH, Galvani AP. Ebola vaccination in the Democratic Republic of the Congo. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 10178-10183. PMID: 31036657, PMCID: PMC6525480, DOI: 10.1073/pnas.1817329116.Peer-Reviewed Original ResearchConceptsContacts of casesImpact of vaccinationFrontline healthcare workersEbola vaccinationEbola vaccineVaccination programHealthcare workersLong-range disseminationVaccination campaignCase confirmationEbola transmissionHigh-risk regionsEbola riskVaccinationFuture outbreaksRiskEarly implementationEbolaLevel of riskDemocratic RepublicGlobal spreadOutbreakVaccineInfectionDoses
2017
Effectiveness of UNAIDS targets and HIV vaccination across 127 countries
Medlock J, Pandey A, Parpia AS, Tang A, Skrip LA, Galvani AP. Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 4017-4022. PMID: 28320938, PMCID: PMC5393239, DOI: 10.1073/pnas.1620788114.Peer-Reviewed Original ResearchConceptsHIV/AIDS 95Joint United Nations ProgrammeOngoing clinical trialsRate of diagnosisBenefits of preventionAntiretroviral therapyHIV vaccinationViral suppressionUNAIDS targetsHIV controlUnited Nations ProgrammeHIV vaccineIncident casesClinical trialsHIV pandemicEnormous morbidityEfficacy vaccineEconomic burdenNew infectionsVaccine developmentDiagnostic approachNations ProgrammeVaccinePreventionTreatment